Effect of trospium chloride therapy on intraocular pressure and tear secretion in overactive bladder patients

Abstract

Trospium chloride decreases the symptoms in female OAB patients. Trospium chloride can be safely used in female OAB patients with normal IOP and no comorbidity as regards IOP changes as it did not cause a significant change in IOP in these patients. Pre-treatment and post-treatment dry eye symptoms of OAB patients about to start using trospium chloride should be queried beforehand as it can cause a statistically significant decrease in tear secretion. We concluded that it would be appropriate to refer the patients to an ophthalmologist before starting the drug if relevant symptoms are present.

Comparision effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: A prospective study

“…Turkoglu et al evaluated daily 1x1 administration of oral trospium to 80 female OAB patients and IOP changes before treatment as well as in the fourth and twelfth weeks of treatment. No significant difference was found in the study for IOP changes in the fourth and twelfth weeks compared to pretreatment (p=0.251, p=0.340, respectively), however, it was reported that trospium significantly reduced tear secretion (26). Likewise, in another study conducted by Turkoglu et al in 2015, no significant difference was observed in IOP values at commencement, the fourth week, or the twelfth week of daily 1x1 oral solifenacin in 93 female OAB patients (27).…”

Implicaciones clínicas del tratamiento de la vejiga hiperactiva en la patología oftalmológica

“…Esto puede ser importante ya que los síntomas de ojo seco pueden empeorar con el tratamiento. Los pacientes con vejiga hiperactiva que hayan sido diagnosticados previamente de ojo seco y que necesitan anticolinégicos deben de ser enviados al oftalmólogo antes de iniciar el tratamiento para que éste les dé unas pautas a seguir (178).…”